Fig. 3From: Comparative effectiveness of beta-interferons and glatiramer acetate for relapsing-remitting multiple sclerosis: systematic review and network meta-analysis of trials including recommended dosagesPairwise meta-analyses for time to progression. IFN: interferon, GA: glatiramer acetate, IM: intramuscular, SC: subcutaneous; TTP3: time to progression confirmed at 3 months; TTP6: time to progression confirmed at 6 monthsBack to article page